全文获取类型
收费全文 | 8454篇 |
免费 | 387篇 |
国内免费 | 69篇 |
专业分类
耳鼻咽喉 | 81篇 |
儿科学 | 167篇 |
妇产科学 | 83篇 |
基础医学 | 992篇 |
口腔科学 | 128篇 |
临床医学 | 569篇 |
内科学 | 2062篇 |
皮肤病学 | 106篇 |
神经病学 | 623篇 |
特种医学 | 346篇 |
外科学 | 1885篇 |
综合类 | 27篇 |
现状与发展 | 1篇 |
预防医学 | 153篇 |
眼科学 | 110篇 |
药学 | 531篇 |
中国医学 | 8篇 |
肿瘤学 | 1038篇 |
出版年
2023年 | 68篇 |
2022年 | 125篇 |
2021年 | 190篇 |
2020年 | 119篇 |
2019年 | 161篇 |
2018年 | 191篇 |
2017年 | 168篇 |
2016年 | 228篇 |
2015年 | 226篇 |
2014年 | 286篇 |
2013年 | 338篇 |
2012年 | 535篇 |
2011年 | 580篇 |
2010年 | 366篇 |
2009年 | 321篇 |
2008年 | 542篇 |
2007年 | 596篇 |
2006年 | 589篇 |
2005年 | 580篇 |
2004年 | 597篇 |
2003年 | 537篇 |
2002年 | 518篇 |
2001年 | 74篇 |
2000年 | 63篇 |
1999年 | 84篇 |
1998年 | 113篇 |
1997年 | 92篇 |
1996年 | 92篇 |
1995年 | 76篇 |
1994年 | 72篇 |
1993年 | 58篇 |
1992年 | 55篇 |
1991年 | 36篇 |
1990年 | 40篇 |
1989年 | 26篇 |
1988年 | 27篇 |
1987年 | 17篇 |
1986年 | 16篇 |
1985年 | 14篇 |
1984年 | 14篇 |
1983年 | 11篇 |
1982年 | 13篇 |
1981年 | 11篇 |
1980年 | 11篇 |
1979年 | 5篇 |
1978年 | 13篇 |
1977年 | 2篇 |
1976年 | 3篇 |
1966年 | 2篇 |
1936年 | 2篇 |
排序方式: 共有8910条查询结果,搜索用时 15 毫秒
91.
92.
Shuaizhang Li Jinghua Zhao Ruili Huang Jameson Travers Carleen Klumpp-Thomas Wenbo Yu Alexander D. MacKerell Jr. Srilatha Sakamuru Masato Ooka Fengtian Xue Nisha S. Sipes Jui-Hua Hsieh Kristen Ryan Anton Simeonov Michael F. Santillo Menghang Xia 《Environmental health perspectives》2021,129(4)
Background: Inhibition of acetylcholinesterase (AChE), a biomarker of organophosphorous and carbamate exposure in environmental and occupational human health, has been commonly used to identify potential safety liabilities. So far, many environmental chemicals, including drug candidates, food additives, and industrial chemicals, have not been thoroughly evaluated for their inhibitory effects on AChE activity. AChE inhibitors can have therapeutic applications (e.g., tacrine and donepezil) or neurotoxic consequences (e.g., insecticides and nerve agents).Objectives: The objective of the current study was to identify environmental chemicals that inhibit AChE activity using in vitro and in silico models.Methods: To identify AChE inhibitors rapidly and efficiently, we have screened the Toxicology in the 21st Century (Tox21) 10K compound library in a quantitative high-throughput screening (qHTS) platform by using the homogenous cell-based AChE inhibition assay and enzyme-based AChE inhibition assays (with or without microsomes). AChE inhibitors identified from the primary screening were further tested in monolayer or spheroid formed by SH-SY5Y and neural stem cell models. The inhibition and binding modes of these identified compounds were studied with time-dependent enzyme-based AChE inhibition assay and molecular docking, respectively.Results: A group of known AChE inhibitors, such as donepezil, ambenonium dichloride, and tacrine hydrochloride, as well as many previously unreported AChE inhibitors, such as chelerythrine chloride and cilostazol, were identified in this study. Many of these compounds, such as pyrazophos, phosalone, and triazophos, needed metabolic activation. This study identified both reversible (e.g., donepezil and tacrine) and irreversible inhibitors (e.g., chlorpyrifos and bromophos-ethyl). Molecular docking analyses were performed to explain the relative inhibitory potency of selected compounds.Conclusions: Our tiered qHTS approach allowed us to generate a robust and reliable data set to evaluate large sets of environmental compounds for their AChE inhibitory activity. https://doi.org/10.1289/EHP6993 相似文献
93.
Yukihiro Yokoyama Masato Nagino Hideki Nishio Tomoki Ebata Tsuyoshi Igami Yuji Nimura 《Journal of hepato-biliary-pancreatic sciences》2007,14(5):447-454
The clinical application of portal vein embolization (PVE) has contributed to improving the postoperative outcome of hilar cholangiocarcinoma. The enlarged nonembolized lobe after PVE protects the patient from postoperative hepatic failure, due to the increased functional reserve, and shortens the hospital stay. Although numerous reports have shown beneficial effects of PVE on postoperative outcome after extended hepatectomy, no randomized controlled study has been performed so far. It is urgent to establish a “gold standard” of PVE, because the indications, approach to the portal vein, types of embolic materials, and methods used to evaluate the function of the future liver remnant are variable among institutions. The indications and procedures of PVE for hilar cholangiocarcinoma may be different from those for hepatocellular carcinoma or colorectal metastasis, because, in many patients with hilar cholangiocarcinoma, biliary cancer is associated with biliary obstruction and cholangitis. This review article summarizes the contribution of PVE to the outcome of postoperative management in patients with hilar cholangiocarcinoma needing extended hepatectomy. We also describe our PVE procedure, which has been established from our experience of more than 240 cases of biliary cancer. Furthermore, the drawbacks of PVE, which may reduce the pool of candidates for surgery, are also discussed. 相似文献
94.
Hideo Yamamoto Naokazu Hayakawa Katsura Hamaguchi Shunichiro Komatsu Masato Nagino Yuji Nimura 《Journal of hepato-biliary-pancreatic sciences》1995,2(2):184-189
A rare case of nonfunctioning islet cell carcinoma associated with tumor thrombi in both the portal and splenic veins is reported. The patient, a 49-year-old male, had a 2-year history of occasional abdominal pain. Computed tomography (CT) disclosed a huge mass in the body of the pancreas, and celiac arteriogram showed a tumor stain in the body and tail of the pancreas. Percutaneous transhepatic portography (PTP) demonstrated an irregular filling defect, indicating intraportal tumor growth. Curative surgery, which included total pancreatectomy with combined resection (50 mm in length) and reconstruction of the portal vein, distal gastrectomy, and partial resection of the transverse colon, was performed. Histological examination of the surgical specimen led to a diagnosis of nonfunctioning islet cell carcinoma with a negative immunohistochemical stain for insulin, glucagon, somatostatin, and adrenocorticotropic hormone. The patient has been well for 38 months to date without any sign of tumor recurrence. Our experience with this case has introduced a radical resection for islet cell tumor of the pancreas, even if the tumor has extended into the portal vein. 相似文献
95.
Masato Maeda MD Dr Masaaki Kanayama MD Yasushi Hasumura MD Jugoro Takeuchi MD Toshikazu Uchida MD 《Digestive diseases and sciences》1988,33(11):1487-1490
Summary A 56-year-old female with mixed connective tissue disease (MCTD) who developed autoimmune hepatitis is described. Hepatitis was controlled effectively by the corticosteroid therapy. Biopsy of the liver revealed swelling and hydropic degeneration of hepatocytes, accompanied by Councilman's body formation and focal necrosis. These histological findings differ from those in three previously described cases. A relationship between MCTD and liver involvement appears possible. 相似文献
96.
97.
Effects of HMGB1 on ischemia-reperfusion injury in the rat heart 总被引:1,自引:0,他引:1
Susumu Oozawa Shuji Mori Toru Kanke Hideo Takahashi Keyue Liu Yasuko Tomono Masato Asanuma Ikuko Miyazaki Masahiro Nishibori Shunji Sano 《Circulation journal》2008,72(7):1178-1184
BACKGROUND: Coronary ischemia-reperfusion (I/R) injury causes cardiomyocyte necrosis in a multi-step process that includes an inflammatory reaction. A recent study has suggested that high-mobility group box 1 (HMGB1) is a late mediator of lethal sepsis and an early mediator of inflammation and necrosis following I/R injury. In the present study a neutralizing monoclonal antibody (mAb) for HMGB1 was used to clarify the role of HMGB1 in cardiac I/R injury. METHODS AND RESULTS: Rats underwent 30 min of left coronary artery occlusion followed by 60 min reperfusion. An intravenous injection of anti-HMGB1 mAb or control IgG was administered just before reperfusion. The infarct size was enlarged in the anti-HMGB1 mAb group in comparison with the control group (p<0.05). The treatment of anti-HMGB1 mAb significantly increased the plasma troponin-T and norepinephrine (NE) content in the heart in comparison with the control (p<0.05). Moreover, the production of dihydroxyphenylglycol was reduced in the anti-HMGB1-treated group (p<0.05). CONCLUSION: This study shows for the first time the effects of treatment with neutralizing anti-HMGB1 mAb on I/R injury in the rat heart. The findings support the novel view that I/R-induced HMGB1 may be an important factor in the modulation of interstitial NE. 相似文献
98.
Noboru Fujino Masami Shimizu Hidekazu Ino Masato Yamaguchi Toshihiko Yasuda Mitsuru Nagata Tetsuo Konno Hiroshi Mabuchi 《The American journal of cardiology》2002,89(1):29-33
Familial hypertrophic cardiomyopathy (HC) can be caused by mutations in 9 different genes encoding sarcomere proteins expressed in cardiac muscle. To date, only 13 different mutations in the cardiac troponin T (cTnT) gene have been reported to cause HC. Clinical characteristics and prognosis associated with mutations of this gene have not been well characterized owing to the small size and composition of affected families. The aim of this study was to determine the characteristic phenotype of patients with HC caused by a novel cTnT gene mutation, Lys273Glu. Two hundred Japanese probands with HC were screened for mutations in the cTnT gene. The Lys273Glu missense mutation was present in 9 persons from 2 unrelated pedigrees. They exhibited different cardiac morphologies: 1 had a dilated cardiomyopathy-like feature, 7 had left ventricular hypertrophy with normal left ventricular systolic function, and the 6 of them had asymmetric septal hypertrophy. A 1-year-old boy was not evaluated with echocardiography. The mean maximum wall thickness was 18.0 +/- 5.5 mm (range 8 to 24). There were 7 histories of sudden death in 1 of the 2 families. The Lys273Glu substitution in the cTnT gene shows a high degree of penetrance (100% in persons aged >20 years), a high incidence of sudden death, and a partial transition from hypertrophic to dilated cardiomyopathy. Because the location of a mutation appears to influence the development of a phenotype, we suggest that the precise definition of the disease-causing mutation can provide important prognostic information about affected members. 相似文献
99.
100.
Takao Nishizawa Mitsunori Iwase Hiroaki Kanazawa Sahoko Ichihara Gaku Ichihara Kohzo Nagata Koji Obata Kiyoyuki Kitaichi Toyoharu Yokoi Masato Watanabe Takashi Tsunematsu Yoshihiro Ishikawa Toyoaki Murohara Mitsuhiro Yokota 《Circulation journal》2004,68(11):1051-1060
BACKGROUND: The relationship between enhanced myocardial oxidative stress and impaired beta-adrenergic signaling remains to be characterized during the development of dilated cardiomyopathy. METHODS AND RESULTS: Alterations in myocardial oxidative stress and beta-adrenergic signaling, as well as left ventricular (LV) functional and structural changes, were evaluated during the development of cardiomyopathy in TO-2 hamsters; F1B hamsters served as controls. LV dysfunction was first apparent at 8 weeks of age and deteriorated thereafter in the TO-2 hamsters. At 32 weeks, the animals exhibited heart failure with an increased plasma norepinephrine concentration. Cardiac myolysis, as demonstrated by elevated plasma concentration of cardiac troponin T, peaked at 8 weeks. The glutathione redox ratio revealed increased oxidative stress in the LV myocardium in TO-2 hamsters even at 4 weeks and became manifest after 8 weeks. The hearts of TO-2 hamsters had significantly reduced superoxide dismutase activity from 8 weeks onward compared with control hamsters. However, glutathione peroxidase activity was unchanged at any time point. The LV functional response to isoproterenol was markedly reduced at 8 weeks, without any apparent changes in the amount of beta-adrenergic signaling molecules, and it deteriorated thereafter. Adenylyl cyclase activity was significantly decreased, despite increased amounts of both G(s) alpha mRNA and protein, in the LV myocardium at 18 weeks. CONCLUSIONS: Myocardial oxidative stress is actually enhanced in the initial development of LV dysfunction. Both activation of myocardial oxidative stress and impairment of beta-adrenergic signaling become prominent at the stage of severe LV dysfunction. Myocardial oxidative stress may be involved in the development of beta-adrenergic desensitization. 相似文献